Correspondence 0001683168-26-004049 from Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: May 18, 2026 · CIK: 0001402328 · Accession: 0001683168-26-004049
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295800
Letter
Sunshine Biopharma Inc.
333 Las Olas Way
CU4 Suite 433
Fort Lauderdale, FL 33301
May 18, 2026
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma Inc.
Registration Statement on Form S-1
File No. 333-295800
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma Inc. hereby respectfully requests (i) acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 11:00 a.m. Eastern Time, May 18, 2026, or as soon as practicable thereafter, and (ii) withdrawal of the previously filed request for the above-referenced Registration Statement to be declared effective May 18, 2026 at 5:00 p.m. Eastern time.
Very truly yours,
Sunshine Biopharma Inc.
Show Raw Text
CORRESP 1 filename1.htm Sunshine Biopharma Inc. 333 Las Olas Way CU4 Suite 433 Fort Lauderdale, FL 33301 May 18, 2026 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma Inc. Registration Statement on Form S-1 File No. 333-295800 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma Inc. hereby respectfully requests (i) acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 11:00 a.m. Eastern Time, May 18, 2026, or as soon as practicable thereafter, and (ii) withdrawal of the previously filed request for the above-referenced Registration Statement to be declared effective May 18, 2026 at 5:00 p.m. Eastern time. Very truly yours, Sunshine Biopharma Inc. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty Chief Executive Officer